Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2024.137 | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma) | Prof. YEO Winnie |
| 2025.673 | A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) | Prof. YEO Winnie |
| 2024.342 | A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY-Gastric 01) | Prof. YEO Winnie |
| 2024.096 | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer | Prof. YEO Winnie |
| 2025.307 | ASKHER2-China: Perceptions, attitudes, and behaviors towards the risk of disease recurrence among women with early-stage HER2+ breast cancer in mainland China and Hong Kong | Prof. YEO Winnie |
| 2025.590 | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Prof. YEO Winnie |
| 2025.858 | An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04) | Prof. YEO Winnie |
| 2024.409 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | Prof. YEO Winnie |
| 2025.159 | Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) | Prof. YEO Winnie |
| 2025.620 | A RETROSPECTIVE STUDY ON EFFICACY AND TOLERABILITY OF TRASTUZUMAB DERUXTECAN FOR ADVANCED BREAST CANCER PATIENTS WITH HER2-POSITIVE, HER2-LOW OR HER2-ULTRALOW DISEASE | Prof. YEO Winnie |
| 2025.373 | A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer | Prof. YEO Winnie |
| 2023.629 | A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) | Prof. YEO Winnie |
| 2025.695 | Phase II study of personalized antiemetic regimen based on pharmacogenetic profile for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese breast cancer patients. | Prof. YEO Winnie |
| 2026.230 | A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011) | Prof. YEO Winnie |
| 2006.340 | Predictors of Survival in Patients with Unresectable Hepatocellular Carcinoma-Clinical, Quality of Life and Virological Factors | Prof. YEO Winnie |
| 2009.376 | A Randomized, Double-blind, Multi-centre Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma: The BRISK FL Study | Prof. Yeo Winnie |
| 2009.202 | A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib | Prof. Yeo Winnie |
| 2008.235 | A Multinational, Randomized, Open-Label, Phase 3 Study of Sunitinib Malate versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma | Professor Yeo Winnie |
| 2008.284 | Premature Postmenopausal Symptoms Affecting the Quality of Life of Younger Breast Cancer Survivors in Hong Kong | Prof. YEO Winnie |
| 2011.467 | PROACTYVE pilot: Pilot study of Patient | Prof Yeo Winnie |
| 2008.294 | A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab | Prof Yeo Winnie |
| 2010.235 | Prospective study of soy intake and breast cancer prognosis in Chinese breast cancer survivors | Prof. YEO Winnie |
| 2009.360 | A randomised Phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy | Prof. YEO Winnie |
| 2013.427 | A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma(HCC) | Prof Yeo Winnie |
| 2010.422 | A Phase II trial of BAY 86-9766 plus sorafenib as a first line systemic treatment for hepatocellular carcinoma (HCC) | Prof. Yeo Winnie |
| 2002.230 | "HERA: A Randomized Three-arm Multi-centre Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women with HER2-positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy" | Prof. YEO Winnie |
| 2012.472 | A Two-Cohort, Open-Label, Multicenter, Study of Trastuzumab Emtansine (T-DM1) in HER2 Positive Locally Advanced or Metastatic Breast Cancer Patients who have Received Prior Anti-HER2 and Chemotherapy-Based Treatment | Prof. YEO Winnie |
| 2012.145 | A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study] | Prof. YEO Winnie |
| 2013.088 | A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy | Prof. YEO Winnie |
| 2010.601 | LUX-Breast 2: An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant and/or adjuvant treatment setting | Prof. YEO Winnie |
| 2007.095 | Phase I/II Study of Paclitaxel/ Carboplatin/ RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach | Prof. YEO Winnie |
| 9406(S) | A Prospective Randomized Phase III Study Comparing the Combination of Cisplatin, Doxorubicin, Interferon-Alpha-2B and 5-Fluorouracil to Doxorubicin Alone in the Treatment of Inoperable Hepatocellular Carcinoma | Prof. YEO Winnie |
| 2010.201 | An Open-label, Randomized Phase 3 Study of Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2009.444 | A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2008.395 | Phase I/II Study of Temsirolimus (Torisel) as Novel Therapeutic Drug for Patients with Unresectable Hepatocellular Carcinoma (HCC) - A Correlative Study with Stathmin Over-expression | Prof. YEO Winnie |
| 2015.507 | A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119) |
Prof. YEO Winnie 楊明明 |
| 2014.596 | A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepatocellular Carcinoma (HCC) | Prof. YEO Winnie |
| 2017.072 | A Prospective Study on the Role of Pharmacogenomic Study in Association with Chemotherapy-Induced Nausea and Vomiting | Prof. YEO Winnie |
| 2016.435 | A prospective study of circulating and urinary isoflavones and lignans concentration at 60-m after diagnosis and the risk of recurrence and mortality in Chinese women with early-stage breast cancer | Prof. YEO Winnie |
| 2016.010 | Cancer Health Literacy among Chinese cancer patients in Hong Kong | Prof. YEO Winnie |
| 2017.169 | Open label single arm study for NEPA [oral fixed-dose combination of 300 mg netupitant and 0.50 mg palonosetron] in Hong Kong oncology patients receiving (neo)-adjuvant chemotherapy treatment consists of adriamycin and cyclophosphamide for breast cancer. | Prof. YEO Winnie |
| 2017.320 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer |
Prof. YEO Winnie 楊明明 |
| 2017.356 | China local BRCA testing and exploration of ovarian cancer treatment outcomes of different BRCA status in newly diagnosed epithelial ovarian cancer patients |
Prof. YEO Winnie 楊明明 |
| 2015.696 | RETROSPECTIVE REVIEW OF EFFICACY AND TOLERABILITY OF T-DM1 IN ADVANCED HER2+ BREAST CANCER |
Prof. YEO Winnie 楊明明 |
| 2017.478 | A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer |
Prof. YEO Winnie 楊明明教授 |
| 2014.529 | A randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy | Prof. YEO Winnie |
| 2016.013 | A Randomized Study to Determine the Efficacy and Tolerability of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese breast cancer patients. |
Prof. YEO Winnie 楊明明 |
| 2016.156 | RETROSPECTIVE REVIEW OF TUMOUR CHARACTERISTICS AND OUTCOMES OF BREAST CANCER PATIENTS |
Prof. YEO Winnie 楊明明 |
| 2014.460 | A Retrospective Study to Assess the Role of Prophylactic Anti-viral Therapies for Patients with CD20+ Lymphoma Receiving Anti-B cell Therapies | Prof. YEO Winnie |
| 2014.584 | A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer | Prof. YEO Winnie |
Page 16 of 289.